<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297202</url>
  </required_header>
  <id_info>
    <org_study_id>2019-SR-332</org_study_id>
    <nct_id>NCT04297202</nct_id>
  </id_info>
  <brief_title>SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma</brief_title>
  <acronym>ACA</acronym>
  <official_title>A Phase II, Open-label, Single Arm, Investigator-initiated Trail of An Anti-PD-1 Inhibitor SHR-1210 in Combination With Apatinib in the Perioperative Treatment of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1
      Inhibitor) in Combination With Apatinib in Patients With Hepatocellular Carcinoma(HCC).This
      study aims to evaluate the safety and efficacy of SHR-1210 combination with Apatinib as a
      preoperative treatment of HCC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathologic response</measure>
    <time_frame>6 months</time_frame>
    <description>It is defined as residual tumors less than 10% after neo-adjuvant therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response</measure>
    <time_frame>6 months</time_frame>
    <description>No histologic evidence of malignancy or only the ingredients of carcinoma in situ was found in primary tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response(ORR)</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>It is defined as the proportion of patients whose tumors shrink to a predetermined size and maintain a minimum time limit. It includes the cases of CR and PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival(RFS)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival rates of 6 months and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>It is defined as the time from randomization to death from any cause during the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by the rate of AEs</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Apatinib Combined With SHR-1210 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Combined With SHR-1210 Injection</intervention_name>
    <description>3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle: D1、D15、D31 : SHR-1210 200mg, I.V, q2w； D1-D20 : Apatinib 250 mg, orally, qd; D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation; After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. Three weeks is a treatment cycle with a total of 8 cycles
In each cycle:
D1: SHR-1210 200mg, I.V, q3w; D1-D21: Apatinib 250mg, orally, qd;</description>
    <arm_group_label>Apatinib Combined With SHR-1210 Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient volunteered to participate in the study and signed an informed consent
             form

          2. ≥18 years of age，Male or female

          3. Subjects are diagnosed with histologically or cytologically confirmed HCC

          4. Subjects haven't received any systemic treatment for HCC before admission.

          5. Subjects enrolled must have measurable lesion(s) according to the RECIST 1.1 standard

          6. ECOG performance status of 0 or 1

          7. Life expectancy ≥ 12 weeks

          8. Subjects are diagnosed with resectable stage IIB, stage IIIA HCC cancer.

          9. The main organ's function is normal and it should meet the following criteria(Excludes
             use of any blood components and cell growth factors during the screening period)

               1. Absolute neutrophil count≥1.5×109 /L

               2. Platelets≥80×109/L ;Hemoglobin≥9.0 g/dL; Serum albumin≥3g/dL

               3. Thyroid stimulating hormone (TSH)≤1.0×upper limit of normal(ULN)（If abnormal, T3
                  and T4 levels should be examined at the same time）

               4. Total bilirubin (TBIL)≤1.5×upper limit of normal (ULN); ALT and AST≤1.5×upper
                  limit of normal(ULN); AKP≤ 2.5×upper limit of normal(ULN)

               5. Serum creatinine ≤1.5×ULN or creatinine clearance &gt; 60 mL/minute (using
                  Cockcroft-Gault formula)

        Exclusion Criteria:

          1. Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar
             cell carcinoma; other active malignant tumor except HCC within 5 years or
             simultaneously

          2. Be ready for or previously received organ or allogenic bone marrow transplantation

          3. Moderate-to-severe ascites with clinical symptoms

          4. History of gastrointestinal hemorrhage within 6 months prior to the start of study
             treatment or clear tendency of gastrointestinal hemorrhage.

          5. Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6
             months prior to the start of study treatment.

          6. Known genetic or acquired hemorrhage or thrombotic tendency.

          7. The patient is currently using or has recently used (within 10 days before the start
             of study treatment) aspirin (&gt; 325mg / day (maximum antiplatelet dose) or
             dipyridamole, ticlopidine, clopidogrel and cilostazol.

          8. Thrombosis or thromboembolic event within 6 months prior to the start of study
             treatment.

          9. Cardiac clinical symptom or disease that is not well controlled.

         10. Subjects have uncontrollable hypertension (systolic pressure ≥ 140 mmHg or diastolic
             pressure ≥ 90 mmHg), despite patients have taken the best drug treatment ；Subjects
             have had a hypertensive crisis or hypertensive encephalopathy

         11. Patient develops severe vascular disease within 6 months before the start of study
             treatment.

         12. Patients with severe, unhealed or split wounds and active ulcers or untreated
             fractures

         13. Patients who underwent surgical treatment within 4 weeks prior to the start of study
             treatment.

         14. Factors to affect oral administration (such as patients unable to swallow oral
             medications, malabsorption syndrome etc. situations evidently affect drug absorption).

         15. Patients with gastrointestinal diseases such as intestinal obstruction (including
             incomplete intestinal obstruction) or those who may have caused gastrointestinal
             bleeding, perforation or obstruction.

         16. There is evidence of intragastric gas that cannot be explained by puncture or recent
             surgery.

         17. Previous or current presence of metastasis to central nervous system.

         18. Subjects have history of hepatic encephalopathy.

         19. The subject has an interstitial lung disease that is symptomatic or may interfere with
             the discovery or management of suspected drug-related lung toxicity; previous and
             current subjects with a history of pulmonary fibrosis, interstitial pneumonia,
             pneumoconiosis, drug-associated pneumonia, severe impaired lung function, etc.

         20. The patient has any active autoimmune disease or a history of autoimmune disease
             expected relapse.

         21. Severe infection within 4 weeks prior to the start of study treatment.

         22. A history of immunodeficiency, including HIV-positive or other acquired, congenital
             immunodeficiency disease.

         23. Prior therapy with any anti-PD-1/PD-L1 drug (specifically targeting T-cell
             co-stimulation or checkpoint pathways), Sorafenib or Apatinib.

         24. Subjects were vaccinated with live attenuated vaccine within 28 days before the first
             dose or expected to receive this vaccine within 60 days after the last dose or during
             the study period.

         25. Treatment of other investigational product(s) within 28 days prior to the start of
             study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuehao Wang</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuehao Wang</last_name>
    <phone>86-025-68303211</phone>
    <email>Wangxh@njmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuehao Wang</last_name>
      <phone>86-025-68303211</phone>
      <email>wangxh@njmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>the Perioperative Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

